Veterinary Practice Valuation Multiples in 2026: How to Read the Headlines

Veterinary-practice owners hear striking numbers about sale multiples. The problem is not that every number is false. The problem is that the context often disappears by the time the number reaches the owner.

“Veterinary practices are selling at 13 times EBITDA” is incomplete. Whose EBITDA? Which practices? Which buyers? How many deals? Was that total consideration or cash at closing? Was owner replacement compensation already included? What happened to retained equity, earnouts, and seller notes?

Before using a multiple to price your practice, reconstruct the full sentence behind it.

This article focuses on interpreting veterinary market multiples and deal terms. For the complete valuation framework, see How to Value a Veterinary Practice; for adjustment evidence, see Veterinary Practice Valuation Add-Backs.

What one current 2026 market report shows

Ackerman Group’s H1 2026 report provides a useful, current view of its own general-practice transaction sample:

H1 2026 measure	Ackerman-reported result
GP hospitals transacted in the sample	20
Observed EBITDA range	8x–16x
Weighted-average GP multiple	13.4x
Average for large practices	14.7x
Average for other GP practices	11.8x
Average cash at closing	8.7x, or 65% of total consideration

The same report explicitly warns that the 13.4x weighted average is being pulled upward by a smaller group of large, highly profitable practices. It describes large practices as having scale, strong EBITDA, stable DVM teams, and room to grow, while reporting that multiples for most other practices had been flat for more than two years (Ackerman Group Q2 2026 market update).

That is valuable market evidence. It is not a universal pricing table. It comes from one adviser’s 20-hospital GP sample and is most relevant when your practice and deal resemble the practices and buyers represented.

Why the average can mislead an owner

Imagine five practices sell at 8x EBITDA and one much larger practice sells at 16x. If the large practice produces far more EBITDA, a dollar-weighted average can sit near the top of the range even though most practices sold closer to the bottom.

That does not make the weighted average wrong. It makes it easy to misuse.

When someone quotes a multiple, ask:

1. Is the figure a simple average, median, or EBITDA-weighted average?
2. How many closed transactions are in the sample?
3. Are they general, emergency, specialty, equine, or mixed-animal practices?
4. How many DVMs and how much adjusted EBITDA did they have?
5. Were the sellers major producers?
6. Does the number represent total consideration or cash at close?
7. Were multiple buyers competing?
8. When did the deals close?

A multiple does not create value by itself

The basic shorthand is:

Indicated enterprise value = normalized earnings × selected multiple

Both halves matter.

If the practice reports $700,000 of EBITDA but a buyer must add $200,000 of replacement clinical and management cost, the buyer may underwrite $500,000 of adjusted EBITDA. Applying 12x to the unadjusted number produces $8.4 million. Applying it to the buyer’s $500,000 produces $6 million. The multiple did not change; the defensible earnings base did.

This is why SDE and EBITDA cannot be swapped casually. A high multiple applied to the wrong earnings definition is not a premium valuation. It is a category error.

Fair market value and investment value are not interchangeable

A veterinarian buying a practice to operate personally may focus on the income available to one owner and on what acquisition financing can support. A corporate buyer may see different economics because it has centralized systems, regional density, purchasing power, recruiting capacity, or strategic goals.

VetPartners distinguishes fair market value used in veterinarian-to-veterinarian transactions from investment value to a particular buyer. Its veterinary valuation guidance also cautions that corporate deal terms—cash, equity, promissory notes, earnouts, and leases—can be as important as the multiple (VetPartners: What’s New in Veterinary Practice Valuation).

So two buyers can rationally offer different prices for the same practice. That does not mean the practice has one “real” multiple and one fake multiple. It means value is being measured under different buyer economics and deal structures.

What tends to move a veterinary multiple

Current veterinary market commentary and the broader valuation framework point repeatedly to a few core drivers:

Scale and earnings

Larger, reliably profitable practices tend to attract more sophisticated buyers and may support higher multiples. Size alone is not enough; the earnings must survive diligence.

DVM stability and owner dependence

A buyer is more likely to pay for earnings that can continue after the seller reduces clinical work. Stable associates, reasonable employment terms, and distributed production improve transferability.

Growth quality

Revenue growth created by repeatable demand and sound operations is more valuable than a temporary price increase, one unusual year, or deferred expenses. The AVMA’s 2026 report introduction notes that gross revenue per FTE veterinarian fell in 2025 for companion-animal-exclusive and companion-animal-predominant practices, underscoring the need to examine productivity rather than assume industry-wide growth (AVMA 2026 report introduction). VHMA’s January 2025 practice commentary similarly reported that revenue per patient in its observed data rose faster than overall revenue while visits weakened—a reminder that price can mask lower volume (VHMA KPI commentary, January 2025).

Facilities and capacity

A sound facility, workable lease, and room for additional production can support growth. Deferred maintenance, an expiring lease, or a building that constrains the doctor team can create risk.

Buyer competition

One offer shows one buyer’s price. A well-run process with several credible buyers can reveal whether strategic interest exists. Competition may improve price or terms, but it cannot make unsupported earnings survive diligence.

Headline value is not cash at close

Ackerman’s H1 2026 sample reported cash at closing equal to 65% of total consideration on average. The rest could include retained practice ownership, parent-company equity, seller notes, or other deferred value.

Those components have different risks, timing, liquidity, and tax treatment. A $10 million offer with $6.5 million in cash is not economically identical to a $10 million all-cash offer. Nor is it automatically worse; retained equity may have upside. The point is to compare components, obligations, and risks—not just the largest number on the first page of a letter of intent.

Use the range as a reasonableness check

Use market multiples as a range and a reasonableness check:

1. Normalize the correct earnings measure.
2. Identify the likely buyer group.
3. Select data from practices similar in size, type, and risk.
4. Date-stamp the market evidence.
5. Show a low, expected, and high case.
6. Explain which facts move the practice within the range.
7. Separate total consideration, cash at close, and estimated owner proceeds.

The strongest valuation is not the one with the highest multiple. It is the one whose assumptions a buyer, lender, appraiser, and owner can all see and challenge.

Get a free practice valuation

Compare a revenue cross-check with an earnings-based range and see which inputs move your number most.

Try PracticeValuator free →

Article sources

• Ackerman Group Q2 2026 Veterinary Industry Market Update — current adviser-reported GP transaction sample, multiples, sample size, and cash-at-close data.
• Ackerman Group Q1 2026 Veterinary Industry Market Update — buyer underwriting factors and Q1 sample.
• VetPartners: What’s New in Veterinary Practice Valuation — fair market versus investment value and deal-term context.
• AVMA 2026 Economic State of the Profession introduction — current productivity direction.
• VHMA KPI commentary, January 2025 — price, revenue, and visit-volume context from observed practices.